You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages

Authors

  • Da-Liang Ou Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Chia-Wei Chen Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Chia-Lang Hsu Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Medical Research, National Taiwan University Hospital, Taipei, TaiwanGraduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Chih-Hung Chung Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming University, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Zi-Rui Feng Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Bin-Shyun Lee Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Ann-Lii Cheng Department of Oncology, National Taiwan University Hospital, Taipei, TaiwanNational Taiwan University Cancer Center, Taipei, TaiwanDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Muh-Hwa Yang Institute of Clinical Medicine, National Yang-Ming University, Taipei, TaiwanDivision of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan PubMed articlesGoogle scholar articles
  • Chiun Hsu Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, TaiwanDepartment of Oncology, National Taiwan University Hospital, Taipei, TaiwanNational Taiwan University Cancer Center, Taipei, Taiwan PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Chiun Hsu; chsu1967{at}ntu.edu.tw; Professor Muh-Hwa Yang; mhyang2{at}vghtpe.gov.tw
View Full Text

Citation

Ou D, Chen C, Hsu C, et al
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Journal for ImmunoTherapy of Cancer 2021;9:e001657. doi: 10.1136/jitc-2020-001657

Publication history

  • Accepted December 15, 2020
  • First published March 22, 2021.
Online issue publication 
February 10, 2022

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.